Survodutide: The Dual GLP-1/Glucagon Liver Drug

Survodutide

62% MASH Improvement

In a Phase 2 NEJM trial, 62% of patients on survodutide 4.8 mg achieved MASH improvement with no worsening of fibrosis, compared to 14% on placebo.

Sanyal et al., NEJM, 2024

Sanyal et al., NEJM, 2024

View as image

Most GLP-1 drugs suppress appetite. Survodutide does that and simultaneously activates glucagon receptors in the liver, directly accelerating hepatic fat metabolism. This dual mechanism produced striking results in a 2024 New England Journal of Medicine Phase 2 trial: 62% of patients with metabolic dysfunction-associated steatohepatitis (MASH) on survodutide 4.8 mg achieved histologic improvement with no worsening of fibrosis, versus 14% on placebo.^[1] The FDA granted survodutide Breakthrough Therapy Designation for MASH in 2024, and two Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) are now underway. For how this drug compares to other dual agonists, see How Survodutide Differs from Other Dual Agonists. For the MASH-specific evidence, see Survodutide and MASH: Why This Drug Focuses on Liver Fat. For weight loss data specifically, see Survodutide Clinical Trial Data: Weight Loss and Metabolic Outcomes.

How Survodutide Works: Two Receptors, Two Pathways

Survodutide (BI 456906, developed by Boehringer Ingelheim and Zealand Pharma) is a peptide that simultaneously activates two receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). These two pathways produce complementary metabolic effects.

The GLP-1 receptor side

GLP-1R activation does what semaglutide and liraglutide do: it reduces appetite by acting on hypothalamic neurons, slows gastric emptying to prolong satiety after meals, and improves insulin secretion in a glucose-dependent manner. This side of survodutide's action is responsible for appetite suppression and improved glycemic control.

The glucagon receptor side

GCGR activation is the distinctive element. Glucagon, historically viewed as a counter-regulatory hormone that raises blood sugar, also stimulates hepatic fat oxidation, increases energy expenditure, and promotes amino acid catabolism in the liver. Thomas et al. documented the pharmacological profiling that led to survodutide's selection as a clinical candidate, demonstrating that GCGR engagement increased hepatic nicotinamide N-methyltransferase (NNMT) mRNA expression by 15- to 17-fold and plasma fibroblast growth factor-21 (FGF21) concentrations by up to sevenfold versus vehicle in preclinical models.^[2]

The key insight behind survodutide: combining GLP-1R and GCGR activation produces greater weight loss and liver fat reduction than either receptor alone. The GLP-1R component prevents the hyperglycemia that pure glucagon agonism would cause, while the GCGR component adds a direct hepatic metabolic effect that pure GLP-1R agonists lack. Thomas et al. selected survodutide from 19 candidate dual agonists specifically for this balance, choosing a molecule that engaged the GCGR robustly enough for superior weight loss while matching semaglutide's antidiabetic efficacy.^[2]

For background on how glucagon operates as a metabolic hormone, see Glucagon: The Other Pancreatic Peptide That Raises Blood Sugar.

Peptide Structure and Design

Survodutide is a 29-amino-acid peptide based on a modified glucagon sequence engineered to also activate the GLP-1 receptor. Like semaglutide and other long-acting GLP-1 agonists, survodutide is acylated with a fatty acid side chain that enables albumin binding in the bloodstream. This albumin binding extends the peptide's half-life to approximately 60-70 hours, allowing once-weekly subcutaneous dosing.

The peptide's amino acid sequence was optimized to achieve a specific ratio of GCGR to GLP-1R activation. Thomas et al. tested 19 different dual agonist candidates, measuring cAMP production in Chinese hamster ovary cells expressing human GCGR and GLP-1R.^[2] The candidates varied in their relative potencies at each receptor. Survodutide was selected not for maximal potency at either receptor individually, but for the balance that produced the best combination of weight loss (GCGR-driven) and glycemic control (GLP-1R-driven) in preclinical models.

This design philosophy differentiates survodutide from other dual agonists. Mazdutide (IBI362), the Chinese competitor, uses a different peptide backbone and achieves a different GCGR/GLP-1R activation ratio. Pemvidutide uses yet another structural approach. The optimal ratio of glucagon to GLP-1 receptor activation for different disease indications (obesity vs. MASH vs. T2D) remains an active area of investigation.

How Survodutide Acts in the Brain

While the glucagon receptor component works primarily in the liver, survodutide also acts centrally to suppress appetite. Recent preclinical evidence indicates that survodutide accesses the brain through circumventricular organs, regions where the blood-brain barrier is naturally permeable, including the area postrema, the subfornical organ, and the median eminence.

Once inside these access points, survodutide activates neurons in the hypothalamic arcuate nucleus and the nucleus of the solitary tract, the same appetite-regulating circuits targeted by semaglutide and other GLP-1R agonists. The dual agonist approach may produce additional satiety signals through glucagon receptor-expressing neurons in the brainstem, potentially explaining why gastrointestinal side effects are more frequent with survodutide than with selective GLP-1R agonists.

This central mechanism of action is relevant for another emerging application of GLP-1R agonists: addiction and reward behavior. For how GLP-1 receptors in brain reward centers affect behavior beyond appetite, see GLP-1 Receptors in the Brain's Reward Center: The Addiction Connection.

Why MASH Is the Target: A Disease Without Adequate Treatment

Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) affects an estimated 5-6% of the global adult population. Unlike simple fatty liver (steatosis), MASH involves hepatocyte injury, inflammation, and progressive fibrosis that can advance to cirrhosis, liver failure, and hepatocellular carcinoma. Until resmetirom (Rezdiffra) received FDA approval in March 2024 as the first drug specifically for non-cirrhotic MASH with moderate to advanced fibrosis, there was no pharmacological treatment approved for the condition.

The unmet need remains enormous. Resmetirom is a thyroid hormone receptor-beta agonist that works through a completely different mechanism than survodutide. Weight loss drugs like semaglutide reduce liver fat as a secondary benefit of weight reduction, but they do not directly target hepatic metabolism. Survodutide's dual agonism is designed to address MASH from two directions simultaneously: reducing caloric intake through GLP-1R-mediated appetite suppression, and directly accelerating hepatic fat catabolism through GCGR activation.

The MASH Trial: 62% Improvement in NEJM

The Phase 2 trial published in the New England Journal of Medicine represents survodutide's most compelling clinical data to date.^[1]

Trial design

Sanyal et al. randomly assigned 293 adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at 2.4, 4.8, or 6.0 mg, or placebo. The trial lasted 48 weeks: a 24-week rapid-dose-escalation phase followed by a 24-week maintenance phase.

Primary results

Improvement in MASH with no worsening of fibrosis:

• Survodutide 2.4 mg: 47%
• Survodutide 4.8 mg: 62%
• Survodutide 6.0 mg: 43%
• Placebo: 14%

The P-value for the quadratic dose-response curve was less than 0.001. The 6.0 mg dose performed worse than 4.8 mg, a pattern attributed to higher discontinuation rates from gastrointestinal side effects at the highest dose.

Liver fat reduction

A decrease in liver fat content by at least 30%:

• 2.4 mg: 63%
• 4.8 mg: 67%
• 6.0 mg: 57%
• Placebo: 14%

Fibrosis improvement

Improvement in fibrosis by at least one stage:

• 2.4 mg: 34%
• 4.8 mg: 36%
• 6.0 mg: 34%
• Placebo: 22%

The fibrosis improvement was modest and not as statistically robust as the MASH improvement, a result consistent with the understanding that fibrosis reversal is slower and requires longer treatment duration than steatohepatitis resolution. For comparison, see how semaglutide approaches the same liver target via different mechanisms in Semaglutide for Liver Fat: What the MASH Data Shows.

The Obesity Trial: Up to 14.9% Weight Loss

A separate Phase 2 trial evaluated survodutide for obesity in people without diabetes.^[3]

Le Roux et al. enrolled 386 participants (BMI 27 kg/m2 or above, aged 18-75) across 43 centers in 12 countries and randomly assigned them to survodutide at 0.6, 2.4, 3.6, or 4.8 mg, or placebo once weekly for 46 weeks (20 weeks dose escalation, 26 weeks maintenance).

Weight loss results

Mean percentage change in bodyweight from baseline to week 46:

• 0.6 mg: -6.2%
• 2.4 mg: -12.5%
• 3.6 mg: -13.2%
• 4.8 mg: -14.9%
• Placebo: -2.8%

Among participants who reached and maintained the 4.8 mg dose, mean weight loss was 18.7%. The proportion achieving clinically meaningful weight loss thresholds at 4.8 mg: 82.8% lost at least 5% of body weight, 68.8% lost at least 10%, and 54.7% lost at least 15%.

The 14.9% mean weight loss places survodutide in a competitive range with semaglutide 2.4 mg (approximately 15% in the STEP trials) and tirzepatide (15-21% in the SURMOUNT trials), though these comparisons across trials are indirect. For how these drugs compare in the GLP-1 landscape, see Short-Acting vs Long-Acting GLP-1 Agonists: What's the Difference?.

Survodutide vs. Semaglutide: The T2D Head-to-Head

The most informative comparative data comes from Bluher et al., who conducted a randomized trial comparing survodutide at multiple doses to both placebo and open-label semaglutide in people with type 2 diabetes.^[4]

Over 16 weeks, HbA1c decreased by 9.92 to 18.38 mmol/mol across survodutide dose groups. Bodyweight decreased dose-dependently up to 8.7%, with survodutide at 1.8 mg/week or higher producing greater bodyweight reductions than semaglutide (which achieved 5.3%). Klein et al. provided additional perspective in a 2024 review, noting that survodutide's dual mechanism may offer advantages specifically in the subset of type 2 diabetes patients with concurrent MASH or significant hepatic fat accumulation.^[5]

Adverse events occurred in 77.8% of survodutide-treated participants (primarily gastrointestinal), compared to 52.5% with placebo and 52.0% with semaglutide. This higher adverse event rate is the trade-off for the dual agonist approach.

Meta-Analysis Evidence: Pooled Data Across Trials

Two independent meta-analyses have now pooled data across survodutide trials.

Wan et al. analyzed 18 treatment arms with 1029 participants and found significant reductions in weight (mean difference: -8.33 kg), BMI (-4.03 kg/m2), and waist circumference (-6.33 cm) compared to placebo. Subgroup analysis confirmed that longer interventions (over 16 weeks) and higher doses (over 2 mg/week) produced the most significant effects.^[6]

Xiao et al. published a larger meta-analysis in 2025 encompassing 6 randomized controlled trials with 1272 participants. Survodutide significantly reduced HbA1c (weighted mean difference: -0.66%), fasting glucagon levels (-7 pmol/L), and body weight (-6.7 kg) compared to placebo. Greater HbA1c reductions occurred specifically with weekly doses above 2.4 mg, while more pronounced weight and waist circumference effects required both higher doses and treatment durations beyond 16 weeks. Survodutide also produced modest reductions in total cholesterol, triglycerides, and blood pressure.^[7]

Both meta-analyses confirmed a higher risk of treatment discontinuation due to gastrointestinal adverse events, though no significant increase in serious adverse events was observed.

Safety Profile: The GI Trade-Off

Gastrointestinal adverse events dominate survodutide's safety profile. In the MASH trial, rates were:^[1]

• Nausea: 66% survodutide vs. 23% placebo
• Diarrhea: 49% vs. 23%
• Vomiting: 41% vs. 4%
• Discontinuation due to adverse events: 20% vs. 3%

Serious adverse events occurred in 8% with survodutide and 7% with placebo, a minimal difference. The gastrointestinal side effects are similar in type to those seen with other GLP-1R agonists (semaglutide, tirzepatide) but appear somewhat higher in frequency, likely because glucagon receptor activation adds its own GI effects on top of the GLP-1 component.

The inverted dose-response in the MASH trial (6.0 mg working less well than 4.8 mg) is primarily explained by higher dropout rates at the highest dose rather than reduced pharmacological efficacy. More patients in the 6.0 mg group discontinued before the end of the 48-week trial, reducing the evaluable population.

Phase 3: SYNCHRONIZE Trials

Survodutide is being evaluated in multiple Phase 3 programs:

SYNCHRONIZE-1 (NCT06066528): A randomized, double-blind trial in adults with obesity, comparing survodutide to placebo for weight management. Le Roux et al. reported the baseline characteristics of enrolled participants in 2026, noting the trial is fully enrolled and results are expected in the first half of 2026.^[8]

SYNCHRONIZE-2 (NCT06066541): Same design but specifically in people with obesity and type 2 diabetes. Also fully enrolled with results expected in H1 2026.

LIVERAGE: Phase 3 trials evaluating survodutide specifically for MASH with fibrosis, the indication that received FDA Breakthrough Therapy Designation.

SYNCHRONIZE-CVOT: A cardiovascular outcomes trial designed to assess whether survodutide reduces major adverse cardiovascular events in people with obesity.

If Phase 3 results confirm Phase 2 efficacy, survodutide could reach the market by 2027-2028.

Where Survodutide Fits in the Landscape

The dual agonist space is increasingly crowded. Survodutide is not the only drug combining GLP-1R with other receptor targets:

Survodutide's competitive advantage centers on its MASH data. The 62% MASH improvement rate in the Phase 2 trial is among the highest reported for any drug in this class. The glucagon component's direct hepatic effects (fat oxidation, reduced lipogenesis) provide a mechanistic rationale for why a GCGR/GLP-1R dual agonist might outperform pure GLP-1R agonists for liver disease specifically. For how retatrutide approaches metabolic disease with an even broader receptor profile, see Retatrutide and Liver Fat: The Surprising MASH Connection. For details on the Chinese competitor, see Mazdutide: The GLP-1/Glucagon Agonist from China's Pipeline.

Limitations and Open Questions

GI tolerability

The 20% discontinuation rate due to adverse events in Phase 2 is a concern. Whether slower dose escalation, GI-targeted co-medications, or patient selection can reduce this rate will be tested in Phase 3.

Fibrosis reversal

While MASH improvement was strong, fibrosis improvement (34-36% vs. 22% placebo) was modest. Whether longer treatment duration or combination therapy is needed to produce meaningful fibrosis reversal is unknown.

Long-term safety

All published survodutide data covers 46-48 weeks at most. Effects on bone density, pancreatic health, thyroid function, and cardiovascular outcomes over years of treatment are unstudied. The SYNCHRONIZE-CVOT trial will address the cardiovascular question.

Weight regain after stopping

No published data exists on what happens when survodutide is discontinued. Based on experience with semaglutide and tirzepatide, weight regain after cessation is likely. Whether the dual agonist mechanism changes this trajectory is unknown.

Cost and access

Pricing has not been announced. Given that semaglutide costs approximately $1,000-1,300/month in the US without insurance, survodutide pricing will be a critical factor for adoption. For how health economists evaluate these drugs, see Cost-Effectiveness of GLP-1s: What Health Economists Say.

Head-to-head trials

No head-to-head randomized trial directly comparing survodutide to semaglutide, tirzepatide, or resmetirom (the approved MASH drug) has been conducted. Cross-trial comparisons are suggestive but not definitive.

The Bottom Line

Survodutide is a dual GLP-1/glucagon receptor agonist that combines appetite suppression with direct hepatic fat metabolism. In a Phase 2 NEJM trial, 62% of MASH patients on survodutide 4.8 mg achieved histologic improvement versus 14% on placebo. A separate obesity trial showed up to 14.9% weight loss over 46 weeks. The FDA granted Breakthrough Therapy Designation for MASH, and Phase 3 trials (SYNCHRONIZE-1, SYNCHRONIZE-2, LIVERAGE) are fully enrolled with results expected in 2026. Gastrointestinal adverse events remain the primary safety concern, with a 20% discontinuation rate in Phase 2. The drug's competitive position depends on Phase 3 outcomes and head-to-head comparisons with other dual and triple agonists.

Frequently Asked Questions

What is survodutide and how does it work?

Survodutide (BI 456906) is a peptide that simultaneously activates GLP-1 and glucagon receptors. The GLP-1 component suppresses appetite and improves blood sugar control. The glucagon component directly stimulates liver fat oxidation and increases whole-body energy expenditure. This dual mechanism targets both caloric intake and hepatic metabolism, producing weight loss and liver fat reduction that may exceed what GLP-1 agonists alone achieve. Thomas et al. (2024) documented how survodutide was selected from 19 dual agonist candidates for its balanced receptor activation profile.

How much weight can you lose on survodutide?

In a Phase 2 trial of 386 participants without diabetes, survodutide produced mean weight loss of 14.9% at the 4.8 mg dose over 46 weeks, compared to 2.8% with placebo (le Roux et al., Lancet Diabetes and Endocrinology, 2024). Participants who maintained the highest dose lost a mean of 18.7%. At the 4.8 mg dose, 82.8% lost at least 5% of body weight, 68.8% lost at least 10%, and 54.7% lost at least 15%. Phase 3 results are expected in 2026.

Is survodutide FDA approved?

Survodutide is not FDA approved as of March 2026. The FDA granted Breakthrough Therapy Designation for the treatment of non-cirrhotic MASH with moderate or advanced fibrosis in 2024. Multiple Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2 for obesity, LIVERAGE for MASH) are fully enrolled. If Phase 3 results confirm Phase 2 efficacy, regulatory submissions could occur in 2027.

How does survodutide compare to semaglutide?

In a head-to-head randomized trial in people with type 2 diabetes, survodutide at doses of 1.8 mg/week or higher produced greater bodyweight reductions (up to 8.7%) than open-label semaglutide (5.3%) over 16 weeks (Bluher et al., Diabetologia, 2024). Survodutide had more gastrointestinal side effects (77.8% vs. 52.0%). The key mechanistic difference is that survodutide's glucagon receptor activation directly increases hepatic fat oxidation, which semaglutide's pure GLP-1 mechanism does not.

What are survodutide side effects?

Gastrointestinal side effects are the primary concern. In the Phase 2 MASH trial, rates were nausea (66% vs. 23% placebo), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%). These led to discontinuation in 20% of survodutide patients versus 3% on placebo (Sanyal et al., NEJM, 2024). Serious adverse events were similar between groups (8% vs. 7%). The GI effects are typical of GLP-1 agonists but appear somewhat more frequent, likely due to additional glucagon receptor activation.

Does survodutide treat fatty liver disease?

Survodutide showed significant efficacy for MASH (fatty liver disease with inflammation) in a Phase 2 trial. Liver fat decreased by at least 30% in 67% of patients on survodutide 4.8 mg versus 14% on placebo. MASH improved without fibrosis worsening in 62% versus 14%. Fibrosis improved by at least one stage in 36% versus 22% (Sanyal et al., NEJM, 2024). These results led to FDA Breakthrough Therapy Designation, and Phase 3 LIVERAGE trials are evaluating survodutide specifically for MASH.